Evidence map›Paper›PMID 41399253›Full record

ArticleHuman vaccines & immunotherapeutics2025

Pre-vaccine immune profiling in cancer patients identifies correlates of COVID-19 vaccine responses.

Maryam Kazerani, Simeon Mahov, Joslyn Foley, Noah M Merin, So Yung Choi, Joseph Lownik, Alexander M Xu, Larry Milshteyn, Anton Luis Villamejor, Maimoona Nadri and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Maryam KazeraniDivision of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Simeon MahovDivision of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Joslyn FoleyDivision of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Noah M MerinDivision of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
So Yung ChoiBiostatistics Shared Resource, Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Joseph LownikDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Alexander M XuDivision of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Larry MilshteynDivision of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Anton Luis VillamejorDivision of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Maimoona NadriDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Nathalie NguyenDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Elham KazemianDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Omid HamidThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Translational Research & Immunooncolgy, Los Angeles, CA, USA.
Justin DarrahDivision of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jun GongDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ronald PaquetteDivision of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Robert VescioDivision of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Inderjit MehmiThe Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Translational Research & Immunooncolgy, Los Angeles, CA, USA.
Warren G TourtellotteDepartment of Neurology, Neurological Surgery and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
V Krishnan RamanujanDepartment of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Karen L ReckampDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jane C FigueiredoDivision of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Akil MerchantDivision of Hematology and Cellular Therapy, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Funding

Diversity and Determinants of the Immune-Inflammatory Response to SARS-CoV-2U54CA260591 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FIGUEIREDO, JANE C., KARIN, MICHAEL · 2020 to 2024
$9.1M
NCI NIH HHS U54 CA260591
6 · The paper itself

Abstract

mRNA vaccines have been highly effective against SARS-CoV-2-related severe illness and are currently undergoing investigation as anti-cancer therapeutics. Our prior work has shown that patients undergoing cancer therapy have reduced immune responses to mRNA-based vaccines. Therefore, further investigation into immunologic responses in the setting of immune-altered hosts is warranted. In this study, we investigated pre-vaccination peripheral immune cell repertoire from a cohort of 66 patients with cancer on active treatment. Immune cell repertoire was characterized by mass cytometry to identify key immune subsets for COVID-19 vaccine response. Immunological populations were then assessed for their association with spike-specific antibody titers measured by ELISA and the breadth and depth of T-cell response to vaccine by TCR sequencing. Immune features significantly correlated with response were selected using an iterative bootstrapping model. We identified immunological features including abundance and functional state of T and B cells, expression of co-stimulatory and -inhibitory molecules, and presence of innate lymphoid cells, and myeloid-derived suppressor cells correlated with humoral and cellular responses. Our findings suggest that vaccine-induced immune responses could serve as biomarkers of immune fitness, in general and specifically for patients receiving anti-cancer mRNA vaccines, providing insights to tailor future therapeutic strategies for immune-altered patients.

Indexed as

COVID-19COVID-19 VaccinesNeoplasmsAdultAgedAged, 80 and overAntibodies, ViralB-LymphocytesFemaleHumansMaleMiddle AgedSARS-CoV-2Spike Glycoprotein, CoronavirusT-LymphocytesAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, Coronaviruscancerhumoral responseimmune fitnessImmunophenotypingSARS-CoV-2TCR responsevaccine

Identifiers

PMID41399253
PMCPMC12710909

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.